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Abstract
Background: Accurate determination of the extrahepatic extent and intrahepatic distribution of
disease is very important in patients with primary and metastatic liver disease for deciding whether
a patient receives potentially curable surgery or palliative treatment. Our objective was to evaluate
the efficacy of delayed phase FDG-PET/CT imaging in lesion detection and to define its clinical
impact compared to triple-phase contrast enhanced CT (CECT).
Methods: 30 patients underwent delayed phase FDG-PET/CT imaging (90 min whole body scan
followed by a delayed abdominal scan at 120 min). Maximum standard uptake values (SUVs) and
SUV ratios between tumor and normal liver parenchyma (T/N) were evaluated. In addition,
comparison was made to CECT obtained within 10 days of the FDG-PET/CT to evaluate for lesion
concordance within individual liver segments (Couinaud designation).
Results: Sites of primary malignancies included: colorectal (19), breast (3), pancreas (2), lung (2),
carcinoid (2), cholangiocarcinoma (1), and hepatocellular carcinoma (1). There was a significant
increase in SUV value of liver lesions between early and delayed acquisition (P < 0.001). Although
there was not a significant reduction in liver background activity between the two studies, there
was a strong increase in T/N ratio (P < 0.001) allowing better lesion detection by visual inspection.
New lesions were identified in 5 of the 30 patients, which were not appreciated on the early scan.
Delayed phase FDG-PET/CT identified one lesion which was not present on the corresponding
CECT. Delayed phase FDG-PET/CT revealed extrahepatic sites of metastases not appreciated on
CECT in 6 patients.
Conclusion: Delayed phase FDG-PET/CT protocol improved lesion detectability in primary and
metastatic liver disease, revealing new lesions in 17% of the patients. Moreover, FDG-PET/CT
identified extrahepatic disease not seen on CECT in 20% of the patients.
Background
The liver is a frequent site of hematogenous metastases
because of its rich dual blood supply. Local endocrine fac-
tors that promote cell growth and fenestrations in the
sinusoidal endothelium allow tumor emboli arriving via
the blood stream to implant and multiply within the
space of Disse [1]. Common gastrointestinal (GI) malig-
nancies that metastasize to the liver include colonic, pan-
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creatic, gastric, gallbladder, and neuroendocrine tumors.
Previously, patients who presented with liver metastases
were classified as stage IV disease and treatment was met
with great skepticism. However, advances in surgical and
medical therapies over the past two decades have pro-
vided effective treatment options. Improvements in surgi-
cal technique combined with a better understanding of
intrahepatic anatomy have allowed hepatic resections to
be performed with acceptable morbidity. Major hepato-
biliary centers routinely report less than 5% perioperative
mortality for non-cirrhotic patients undergoing partial
hepatectomy [2].
Anatomic resection of liver metastases is now commonly
performed in colorectal cancer patients with isolated int-
rahepatic disease, and the impact has been dramatic with
five year survival rates up to 40% [3]. Patients with extra-
hepatic metastases that are amenable to resection may
also benefit from partial hepatectomy and can achieve five
year survival rates of 28% as reported by Elias et al [4].
Similar results have been demonstrated in resection of pri-
mary liver tumors. Tanaka et al reports three year survival
rates of 89% after partial hepatectomy for hepatocellular
carcinoma meeting Milan criteria (solitary tumor < 5 cm
or up to three nodules < 3 cm) [5]. Surgical resection of
large hepatocellular carcinomas > 10 cm have less impres-
sive outcomes but still can achieve five year survival rates
up to 28% [6].
Radiologic staging of patients with primary or metastatic
liver disease is vital to determine the suitability of partial
hepatectomy [7-9]. The goals of imaging are twofold:
define the extrahepatic extent and intrahepatic distribu-
tion of disease. Triple-phase contrast enhanced CT
(CECT) has been the mainstay of preoperative planning
by providing key anatomical information. MRI can pro-
vide complementary data by evaluating the signal and
enhancement characteristics of liver lesions and may bet-
ter delineate involvement/invasion into adjacent vascular
or biliary structures. MRI, however, has low sensitivity for
detecting extrahepatic disease.
PET/CT with 18F-FDG is an integral tool for the staging of
many malignancies. PET/CT has been shown to improve
the therapeutic management of patients with colorectal
cancer by detecting unsuspected extrahepatic metastases
[10-16]. The value of PET/CT has been questioned for
detection of intrahepatic disease because of the high back-
ground activity in the liver parenchyma due to high glu-
cose metabolism and abundant expression of Glut-1 and
hexokinase II (HK-II). To circumvent the problems inher-
ent to detection of intrahepatic lesions on PET/CT, several
authors have proposed delayed PET/CT imaging and the
results have been encouraging [17-21]. The premise of
dual phase PET/CT is that malignant cells should prefer-
entially accumulate activity more than normal hepato-
cytes thereby improving tumor to background ratios over
time. Our goal was to determine whether dual phase
acquisition PET/CT can improve lesion detectability in
primary and metastatic liver disease and to define its clin-
ical impact compared to CECT.
Methods
Patients
149 consecutive cancer patients evaluated at the Goshen
Cancer Institute over a six month period underwent dual
phase 18F-FDG PET/CT imaging. The studied patients had
known primary malignancies either hepatic in origin or
extrahepatic with suspected liver metastases.
Image Acquisition
Patients were asked to fast for a minimum of six hours
prior to the study and blood glucose levels had to be less
than 200 mg/dl prior to injection of 18F-FDG. All images
were acquired using a dedicated GE Discovery PET/CT
scanner. Initial "early" whole body imaging commenced
90 ± 15 minutes after injection of 15 mCi of 18F-FDG. An
additional "delayed" scan focusing on the liver was
obtained 120 ± 16 minutes after the injection. PET images
were reconstructed using CT attenuation correction, dead
time correction, and decay correction to the beginning of
each scan.
Data Analysis
Early and delayed images were interpreted on the GE
workstation in the axial, coronal, and sagittal planes along
with maximum intensity projection images. Each scan
was reviewed for the presence of liver lesions. Maximum
standardized uptake values (SUVs) were obtained by
drawing three dimensional regions of interest (ROIs)
around each lesion on the early study and the correspond-
ing lesion on the delayed study. Lesions which demon-
strated SUVs greater than background activity with a
minimum value of 3 were defined as positive for metasta-
sis. ROIs were also placed over uninvolved regions of the
liver to obtain SUVs of the background normal liver
parenchyma. The tumor to normal parenchyma ratio (T/
N ratio) was then calculated for each lesion identified on
the early and delayed studies using the following formu-
las:
T/N early = SUV tumor early /SUV background early
T/N delayed = SUV tumor delayed /SUV background delayed
Paired T-Test was used for statistical comparison of early
and delayed tumor SUV values, background SUV values,
and T/N ratios. P values less than 0.05 were considered
statistically significant for all analyses.International Seminars in Surgical Oncology 2007, 4:17 http://www.issoonline.com/content/4/1/17
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In addition to ROI analysis, comparison was made to
CECT obtained within 10 days of the PET/CT to evaluate
for the following parameters: lesion concordance within
individual liver segments (Couinaud designation) and
extrahepatic sites of metastases.
Results
30 of the 149 patients demonstrated liver lesions (13
males and 17 females, mean age 61.1 years, age range 42–
86 years). Sites of primary malignancies included: color-
ectal (n = 19), breast (n = 3), pancreas (n = 2), lung (n =
2), carcinoid (n = 2), cholangiocarcinoma (n = 1), and
hepatocellular carcinoma (n = 1).
54 liver lesions were detected among the 30 patients in
our study. Five of these lesions were not apparent on the
early scan and visualized only on delayed imaging (Figure
1). 46 of the 54 lesions (85%) demonstrated an increase
in SUV value on delayed imaging. Further analysis of the
8 lesions whose SUV did not increase over time reveals
that only one lesion was associated with an SUV decline
of greater than 1 (range 0.1–2.1, median 0.3); and all of
the SUV values remained above 3. T/N ratios increased in
5 of these 8 lesions allowing for better delineation on
delayed imaging. The remaining 3 lesions were clearly
positive on the early scan. Overall, 48 of the 54 liver
lesions (89%) showed an increase in T/N ratio on the
delayed phase. Background SUV values were more varia-
ble but tended to decrease in two thirds of the patients.
Table 1 shows the mean and standard deviations of max-
imum SUVs in malignant liver lesions and normal liver
parenchyma as well as T/N ratios in both early and
delayed acquisitions. Mean SUV values of malignant
lesions increased from 10.5 to 11.5 on delayed imaging
and demonstrated statistical significance with a P value of
less than 0.001. Mean liver background SUVs decreased
slightly from 3.8 to 3.6, but it did not show a significant
difference (P = 0.05). However, there was a strong increase
in T/N ratio (P < 0.001) allowing for better lesion detec-
tion by visual inspection on the delayed scan.
There was concordance of involved liver segments
between CECT and delayed phase FDG-PET/CT in 28 of
30 patients. CECT identified more extensive disease in
one patient with HCC. Delayed phase FDG-PET/CT dem-
onstrated involvement of a new Couinaud segment in one
patient with colorectal carcinoma, which was not present
on the corresponding CECT performed on the same date
(Figure 2). This lesion surfaced on CECT performed 6
months later confirming the validity of the PET/CT find-
ings. Delayed phase FDG-PET/CT revealed extrahepatic
sites of metastases not appreciated on CECT in 6 patients
(Figure 3). Sites of extrahepatic disease not recognized on
CECT included periportal/peripancreatic lymphadenopa-
thy (n = 1), pulmonary nodules (n = 1), and osseous
metastases (n = 4).
Discussion
18F-FDG PET/CT is a valuable tool for the staging of many
malignancies. Although the fusion of anatomic CT data
with the functional information provided by PET has
improved diagnostic accuracy, detection of primary and
metastatic liver lesions remains challenging because of the
high background FDG activity in normal liver paren-
chyma and reconstruction artifacts generated by respira-
tory diaphragmatic motion. FDG uptake in normal and
malignant tissues is dependent on a variety of factors. On
a macroscopic level, malignant cells metabolize glucose at
increased levels because of high energy demands and
therefore show PET positivity since FDG is used as an
energy substrate. More aggressive tumors have higher
energy demands and higher metabolic rates and tend to
be strongly positive on PET. On a molecular level, it is the
expression of Glut 1 and HK-II that allows FDG to enter
the cell, become phosphorylated, and then trapped intra-
cellularly allowing for coincidence detection of positron
emissions. It has been suggested that Glut-1 and HK-II
expression are inversely related in some primary liver
Table 1: Semi quantitative analysis of 18F-FDG uptake in 
metastatic liver lesions on delayed phase PET/CT.
Early Delayed
SUV in malignant lesions 10.2 ± 4.8 11.3 ± 5.0
SUV in normal parenchyma 3.7 ± 0.8 3.4 ± 0.8
T/N ratio 2.9 ± 1.5 3.4 ± 1.5
CECT (top left), early(top right) and delayed phase (bottom)  FDG-PET/CT fusion images of a 46 year old male with lung  carcinoma showing delayed accumulation of FDG in a seg- ment 7 metastatic lesion Figure 1
CECT (top left), early(top right) and delayed phase (bottom) 
FDG-PET/CT fusion images of a 46 year old male with lung 
carcinoma showing delayed accumulation of FDG in a seg-
ment 7 metastatic lesion.International Seminars in Surgical Oncology 2007, 4:17 http://www.issoonline.com/content/4/1/17
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tumors [22]. Cells that have high levels of Glut-1 such as
mass-forming cholangiocarcinoma can easily facilitate
glucose transport into the cell. High intracellular levels of
glucose-6-phosphate may cause downregulation of HK-II
by feedback inhibition. On the other hand, HK-II expres-
sion in high grade hepatocellular carcinoma (HCC) is ele-
vated likely a result of upregulation caused by low levels
of Glut-1 on the cell surface. Both cholangiocarcinoma
and high grade HCC are strongly PET positive; and
although they may have different mechanisms of FDG
uptake, they have a final common pathway of increased
glucose metabolism.
Is there a molecular explanation of why delayed imaging
may facilitate tumor detection and why SUV values
increase over time in malignant cells? The answer may lie
in tumor vascularity. It has been demonstrated that Glut-
1 and HK-II expression is greatest in the central region of
tumors by autoradiography [23]. Aggressive tumors often
have insufficient blood supply leading to hypoxia and
eventual central necrosis. When tumor cells are exposed to
a hypoxic environment, HIF-1α is activated to promote
the transcription of glucose transporters and glycolytic
enzymes. Delayed imaging allows more time for FDG to
migrate to hypoxic areas which have higher regional levels
of Glut-1 and HK-II. Delayed imaging also allows more
time for FDG to reach hypovascular tumors or those with
altered blood supply as a sequella of prior treatments.
Finally, delayed imaging allows for further clearance of
blood pool activity.
Dual phase 18F-FDG PET has been proposed by other
authors for the evaluation of GI malignancies and the
results have been encouraging. Nishiyama et al. reports
increased lesion uptake and increased lesion-to-back-
ground contrast in gallbladder carcinoma on delayed
images; however, the diagnostic performance was
dependent on C-reactive protein levels [17]. Nishiyama
also reports that delayed FDG PET is helpful in pancreatic
cancer by identifying new metastatic foci in 3 of 55
patients [18]. In a study of 12 patients with hepatocellular
carcinoma, Lin et al. found that the mean SUV, T/N ratio,
and diagnostic sensitivity all increased on 2 hour delayed
images. Lin et al. also showed a slight decrease in the
mean SUV of normal liver tissue [19]. Our study did not
show a significant difference between early and delayed
background liver activity; however, this variability in
background activity had little impact on T/N ratios which
still increased in 86% of metastatic lesions our study. This
suggests that it is the retention of FDG in malignant cells
(as determined by Glut-1 and HK-II expression) rather
than clearance of blood pool activity that is the most
important factor in delayed lesion detection. This obser-
vation, however, needs to be correlated with biochemical
analysis.
If dual phase PET/CT can improve the detection of pri-
mary and metastatic liver lesions as we have demon-
strated, should all patients requiring PET/CT for staging
purposes undergo dual phase acquisition? In an era where
curative liver resections are increasingly performed,
appropriate selection of patients for this clinical objective
is imperative. The most important information provided
by radiologic studies, obviously, is to determine whether
an R0 curative resection can be safely performed by iden-
tifying the number and distribution of lesions and their
proximity to major vascular structures and the biliary tree.
In this respect, accurate staging of patients with identifica-
tion of hepatic and extrahepatic distribution of lesions is
very important. The ultimate answer to this question
CECT (left) and delayed phase FDG-PET/CT fusion images  (right) of a 42 year old female with lung carcinoma showing  FDG uptake in periportal/peripancreatic lymph nodes not  clearly demonstrated on CECT Figure 3
CECT (left) and delayed phase FDG-PET/CT fusion images 
(right) of a 42 year old female with lung carcinoma showing 
FDG uptake in periportal/peripancreatic lymph nodes not 
clearly demonstrated on CECT.
Early (top left) and delayed phase (top right) FDG-PET/CT of  a 54 year old female with metastatic colorectal carcinoma  showing a segment 6 lesion not seen on CECT performed on  the same date (bottom left) but surfacing 6 months later  (bottom right) Figure 2
Early (top left) and delayed phase (top right) FDG-PET/CT of 
a 54 year old female with metastatic colorectal carcinoma 
showing a segment 6 lesion not seen on CECT performed on 
the same date (bottom left) but surfacing 6 months later 
(bottom right).International Seminars in Surgical Oncology 2007, 4:17 http://www.issoonline.com/content/4/1/17
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could require prospective studies with larger patient pop-
ulations addressing comprehensive cost-benefit analyses.
Based on the data that is available at this time, we propose
that those patients who are candidates for surgical resec-
tion should undergo dual phase PET/CT with 18F-FDG for
the following reasons. Dual phase acquisition can evalu-
ate the metabolic activity of lesions seen on anatomical
imaging and confirm benign or malignant etiology. Dual
phase PET/CT may identify new metastatic lesions (intra
or extrahepatic) that were not appreciated on conven-
tional imaging modalities. In addition, dual phase PET/
CT may further characterize the response of malignant
lesions to neoadjuvant therapy. All of these considera-
tions have a great impact on surgical planning and may
decide whether a patient is a candidate for curative resec-
tion or whether the patient would benefit from medical
therapy, decisions which are paramount for patient care
and long term survival.
Conclusion
Delayed phase FDG-PET/CT improves lesion detectability
in primary and metastatic liver disease, revealing new
lesions in 17% of the patients. Moreover, FDG-PET/CT
identified extrahepatic sites of metastases not seen on
CECT in 20% of the patients. For these reasons, we pro-
pose that patients with primary or metastatic liver disease
in whom surgical resection is being contemplated should
undergo staging with delayed phase FDG-PET/CT.
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